These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25853942)

  • 21. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
    Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Improvement of fixation in diabetic macular oedema patients under intravitreal ranibizumab treatment].
    Seidensticker F; Reznicek L; Cserhati S; Liegl RG; Langer J; Wolf A; Kampik A; Ulbig M; Haritoglou C; Kernt M
    Klin Monbl Augenheilkd; 2013 May; 230(5):524-9. PubMed ID: 23229224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yutiq - another fluocinolone intravitreal implant for uveitis.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e5-e6. PubMed ID: 34544110
    [No Abstract]   [Full Text] [Related]  

  • 24. Diabetic macular edema.
    Ghazi NG; Scruggs RT; Batchelet AR; Compton MW; Allam SS; Patrie J; Salti HI
    Ophthalmology; 2012 Dec; 119(12):2643.e1. PubMed ID: 23207021
    [No Abstract]   [Full Text] [Related]  

  • 25. Nd:YAG Vitreolysis to Release Anteriorly Lodged Fluocinolone Acetonide Insert.
    Emami-Naeini P
    Ophthalmology; 2021 Jan; 128(1):137. PubMed ID: 33349338
    [No Abstract]   [Full Text] [Related]  

  • 26. Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.
    Testi I; Pavesio C
    Ther Deliv; 2019 Oct; 10(10):621-625. PubMed ID: 31663454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant.
    Bollinger KE; Smith SD
    Curr Opin Ophthalmol; 2009 Mar; 20(2):99-103. PubMed ID: 19248312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease].
    Brunner M; Haueter I; Valmaggia C
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):396-400. PubMed ID: 23629790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant.
    Sims JL; Chee SP
    Eye (Lond); 2010 Jan; 24(1):197-8. PubMed ID: 19325574
    [No Abstract]   [Full Text] [Related]  

  • 30. [Early treatment diabetic retinopathy study (ETDRS) visual acuity].
    Told R; Baratsits M; Garhöfer G; Schmetterer L
    Ophthalmologe; 2013 Oct; 110(10):960-5. PubMed ID: 23779250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
    Jaffe GJ
    Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.
    Jain N; Stinnett SS; Jaffe GJ
    Ophthalmology; 2012 Jan; 119(1):132-7. PubMed ID: 21924503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal.
    Wan W; Stewart JM
    Ocul Immunol Inflamm; 2011 Jun; 19(3):214-5. PubMed ID: 21595540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anterior Chamber Migration of Fluocinolone Acetonide Intravitreal Implant.
    Rishi P; Majumder PD; Biswas J
    JAMA Ophthalmol; 2019 Sep; 137(9):e185931. PubMed ID: 31513241
    [No Abstract]   [Full Text] [Related]  

  • 35. A functional, nonfunctioning Retisert implant.
    Hebson CB; Srivastava SK
    Ocul Immunol Inflamm; 2011 Jun; 19(3):210-1. PubMed ID: 21595538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of sympathetic ophthalmia with the fluocinolone acetonide implant.
    Mahajan VB; Gehrs KM; Goldstein DA; Fischer DH; Lopez JS; Folk JC
    Ophthalmology; 2009 Mar; 116(3):552-557.e1. PubMed ID: 19147232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
    Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
    Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.